The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index; 198 of the 229 sources its claims cite were checked for support.
Evolution of multiple myeloma from a genomic perspective
Open accessAbstract
In this review, we explore the role of complex interactions between genomic evolution, environmental and genetic predispositions, and immune surveillance in disease progression from precursor conditions smoldering multiple myeloma and monoclonal gammopathy of undetermined significance to multiple myeloma (MM). MM has been described to be universally preceded by precursor states, often decades before it is even diagnosed. Genetic predisposition plays an important role in the initial transformation, and is driven by both germline variants and MM-specific loci influencing risk. The reported disparities in occurrence of precursor conditions and MM among racial groups highlights the role of predisposition and the need for broader cohort studies. Early genomic events, such as translocations and hyperdiploidy, are essential in precursor initiation. However, additional factors are usually needed to transform the precursor stages into symptomatic disease, such as positive selection of subclonal populations. This process is affected by aging and environmental factors, such as exposures to Agent Orange and agrochemicals. Therefore, integrating genomic and transcriptomic data with immune profiling or other clinical features is essential for identifying patients with high risk of progressing into MM. Here, we highlight the complexity of myelomagenesis, and underline the importance of state-of-the-art approaches for improved disease prediction.
Overview
CoChat Summary
TL;DR
This review integrates genomic, clinical, and temporal evidence to model how MGUS/SMM precursor conditions evolve into multiple myeloma through early initiating events, genetic predisposition, environmental exposures, and immune surveillance. It argues that many MM cases acquire their tumorigenic genomic profile early, with progression depending on subsequent clonal selection and immune escape.
Key findings
- MM is universally preceded by precursor states MGUS/SMM, often decades before diagnosis; initiating events include IGH translocations and hyperdiploidy (HY). HY can start in the 2nd–3rd decade of life, with additional trisomies/aneuploidies acquired in subsequent decades; when HY and IGH co-occur (~10% of patients), HY always occurs after IGH. In >50% of patients, HY multi-gain events include non-odd chromosomes, most frequently 1q gain, and early 1q appears associated with more aggressive disease.
- Progression is linked to RAS mutations, MYC translocations, APOBEC mutagenesis, and genomic complexity; these can already be observed in some MGUS and low-risk SMM years before progression. Molecular modeling estimates initiation of progressive SMM at approximately 30–40 years, while stable MGUS/SMM show a shorter lag of ~10–20 years; in IGH+HY cases, HY is acquired ~20 years before diagnosis.
- The review proposes three MGUS/SMM groups: an immortalized but untransformed clone; a genomically transformed clone that remains stable under possible immune control (illustrated by the “MAFB paradox”); and a clone with both genomic transformation and immune escape, where progression is “merely a matter of time.”
- Early intervention trials in high-risk SMM show progression-free survival benefit and one recent study demonstrated overall survival advantage, but the field lacks accurate prediction models; high-risk genomic features are underrepresented in SMM trials, and patients with mature MM genomic profiles typically fail to reach MRD negativity.
Methods
- Narrative review integrating historical and recent studies to construct a model of myelomagenesis across temporal, clinical, and genomic dimensions.
- Evidence base includes whole-genome sequencing, SNP arrays, FISH, mass spectrometry, single-cell RNA sequencing, immune profiling, molecular mathematical modeling, and interventional clinical trials; no new primary data are reported.
- Main analysis is a synthesis of genomic evolution, genetic predisposition, environmental exposures, and immune surveillance from MGUS/SMM to MM.
Limitations
- Stated: lack of large, racially heterogeneous cohorts from non-European ancestry limits genetic predisposition and racial disparity investigations; immune microenvironment studies have not defined how the microenvironment changes with external events; accurate prediction models for high-risk SMM are lacking; current MGUS/SMM definitions are clinically based and lack genomic features, immune status, or direct tumor-bulk assessment; early 1q findings need independent validation.
- Evident: as a review, it reports no primary data; temporal models predict initiation timing only in the context of HY; spatial heterogeneity may not be captured by a single bone marrow investigation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
70 Valid · 6 Not valid · 9 Not checked · 39 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Overall, these patterns combined with observations from epidemiological studies suggest a model with three major groups of MGUS/SMM (Figure 3).84,86”
§ Evolution of Multiple Myeloma from a Genomic Perspective > HOW DOES MYELOMA PRECURSOR CONDITION PROGRESS TO MULTIPLE MYELOMA?
What the sources say
- Disputedcites [84] Maura, 2026, Genomics define malignant transformation in myeloma precursor conditions, J Clin Oncol sourceExperimental — accuracy not yet measured
The Results (Genomic Profiling to Define Malignant Transformation; page unavailable) say the proposed workflow divides MGUS and SMM into two genomically distinct entities, not three major groups. The Discussion likewise describes the classification as distinguishing genomic MGUS from genomic MM. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Could not verifycites [86] Rasche, 2017, Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing, Nat Commun sourceExperimental — accuracy not yet measured
The Discussion (Fig. 5; page unavailable) proposes a two-phase model of clonal progression in multiple myeloma, with MGUS mentioned as an earlier stage. Our copy does not describe three major groups of MGUS/SMM; searches for that grouping and for epidemiological evidence found no supporting passage. (LLM, conf=0.73)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Typically, these patients are well captured by integrating independent disease-burden-based prognostic scores (e.g., IMWG and PETHEMA).7,102,103”
§ Evolution of Multiple Myeloma from a Genomic Perspective > HOW DOES MYELOMA PRECURSOR CONDITION PROGRESS TO MULTIPLE MYELOMA?
What the sources say
- Disputedcites [7] Cowan, 2023, Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study, Lancet Haematol sourceExperimental — accuracy not yet measured
The Discussion (page unavailable in our copy) says the 20/2/20 and PETHEMA criteria disagree about which patients are high risk, rather than showing that combining existing scores captures them well. The Results report that PANGEA classified 58% of patients with smouldering myeloma who later progressed as high risk when 20/2/20 had classified them as intermediate or low risk. The paper does not test an integrated IMWG–PETHEMA score. (LLM, conf=0.81)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [102] Pérez-Persona, 2007, New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells, Blood sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) describe a prognostic score that separates MGUS and smoldering myeloma patients into three progression-risk groups. The paper does not show that integrating its score with an IMWG score captures the citing document’s “third-group patients”; it says prospective work would be needed to explore whether its flow-cytometry measure and another risk measure are independent. (LLM, conf=0.84)
- Partly supportedcites [103] Kazandjian, 2021, Carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance for prevention of symptomatic multiple myeloma in patients with high-risk smoldering myeloma: a phase 2 nonrandomized controlled trial, JAMA Oncol sourceExperimental — accuracy not yet measured
The Strengths and Limitations section (page unavailable) says the authors used mutually inclusive criteria to define high-risk smoldering myeloma and that current risk models use disease-burden variables. It does not establish that integrating IMWG and PETHEMA scores captures these patients well; it instead notes substantial discordance between risk models. The paper uses IMWG criteria for myeloma-defining events, rather than identifying an IMWG prognostic score in that comparison. (LLM, conf=0.85)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“While aging plays a critical role in driving these changes, it is well established that environmental factors and exposure to certain substances can significantly alter clonal composition promoting positive selection and accelerating the physiological restriction of the stem cell pool. 25-27”
§ Evolution of Multiple Myeloma from a Genomic Perspective > POSITIVE SELECTION IN HEALTHY INDIVIDUALS AND DURING MYELOMA PATHOGENESIS.
What the sources say
- Partly supportedcites [25] Bolton, 2020, Cancer therapy shapes the fitness landscape of clonal hematopoiesis, Nat Genet sourceExperimental — accuracy not yet measured
The Main section, “Clinical parameters shape the fitness landscape of CH” (page unavailable), says that cancer treatment, smoking, and aging affect the relative fitness of hematopoietic clones in a gene-dependent manner. The “Clonal dynamics” section reports that cancer therapy selects for particular clones. Our copy does not establish that these exposures accelerate the physiological restriction of the stem cell pool. (LLM, conf=0.86)
- Partly supportedcites [26] Santarsieri, 2025, The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study, Lancet Oncol sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says chemotherapy can induce mutations in normal stem cells, and the Results (page unavailable) report substantially higher stem-cell mutation burdens after eBEACOPP treatment. These passages support an effect of substance exposure on stem-cell genomes, but they do not establish positive selection, altered clonal composition, or accelerated restriction of the stem-cell pool. (LLM, conf=0.83)
- Partly supportedcites [27] Spencer Chapman, 2024, Clonal dynamics after allogeneic haematopoietic cell transplantation, Nature sourceExperimental — accuracy not yet measured
The ‘Loss of clonal diversity after HCT’ section (page unavailable) reports that transplant recipients had lower clonal diversity than matched donors, equivalent on average to 12 additional years of ageing. The paper links this to transplant-specific selection and a changed marrow environment, but does not establish that environmental factors or exposure to substances generally accelerate restriction of the stem-cell pool. (LLM, conf=0.87)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A consistent pattern has been observed across most, if not all, tissues: after an initial expansion of the stem cell pool during early life, clonal heterogeneity tends to diminish over time (Figure 1).17-24”
§ Evolution of Multiple Myeloma from a Genomic Perspective > POSITIVE SELECTION IN HEALTHY INDIVIDUALS AND DURING MYELOMA PATHOGENESIS.
What the sources say
- Partly supportedcites [17] Abby, 2023, Notch1 mutations drive clonal expansion in normal esophageal epithelium but impair tumor growth, Nat Genet sourceExperimental — accuracy not yet measured
The Discussion describes expanding NOTCH1-mutant clones that can dominate normal human esophagus, and the ‘Notch1 haploinsufficiency enables epithelial colonization’ section reports increasing mutant coverage with age. This supports age-related clonal dominance in esophageal epithelium, but the paper does not establish an initial expansion of the stem-cell pool during early life or the pattern across most tissues. (LLM, conf=0.84)
- Could not verifycites [18] Brzozowska, 2025, Selection for somatic escape variants in SERPINA1 in the liver of patients with alpha-1 antitrypsin deficiency, Nat Genet sourceExperimental — accuracy not yet measured
The Main and Results sections describe expansion of hepatocyte clones in chronic liver disease, but do not describe an early-life expansion of the stem-cell pool or a decline in clonal heterogeneity with age across tissues. Searches for those developmental and cross-tissue patterns found no passage addressing them (page numbers unavailable). (LLM, conf=0.74)
- Partly supportedcites [19] Coorens, 2025, The somatic mutation landscape of normal gastric epithelium, Nature sourceExperimental — accuracy not yet measured
The ‘Mutation rates of gastric epithelium’ section (page not provided) says gastric glands start as polyclonal units and drift toward monoclonality, supporting declining clonal heterogeneity in that tissue. It does not establish an initial early-life expansion of the stem cell pool or the same pattern across most tissues. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [20] Kakiuchi, 2021, Clonal expansion in non-cancer tissues, Nat Rev Cancer source
- Not checked — no full text of the sourcecites [21] Lawson, 2020, Extensive heterogeneity in somatic mutation and selection in the human bladder, Science source
- Partly supportedcites [22] Martincorena, 2018, Somatic mutant clones colonize the human esophagus with age, Science sourceExperimental — accuracy not yet measured
The Discussion reports that mutant clones colonize much of the esophageal epithelium with age, supporting age-related clonal expansion. The paper does not establish that clonal heterogeneity diminishes across most tissues, nor does it describe an initial expansion of the stem-cell pool in early life. (LLM, conf=0.83)
- Could not verifycites [23] Moore, 2021, The mutational landscape of human somatic and germline cells, Nature sourceExperimental — accuracy not yet measured
The Clonal structures in normal tissues section (p. 3) describes how clonal architecture differs among adult tissues, and the Discussion (p. 6) emphasizes variation in clonal dynamics. Neither passage establishes an early-life expansion of the stem-cell pool followed by declining clonal heterogeneity across most tissues; searches for age-related loss of clonal diversity found no such account in our copy. (LLM, conf=0.72)
- Could not verifycites [24] Ng, 2021, Convergent somatic mutations in metabolism genes in chronic liver disease, Nature sourceExperimental — accuracy not yet measured
No passage from our copy matched the claim. Searches for early-life stem-cell expansion, age-related changes in clonal diversity, and declining clonal heterogeneity across tissues returned no passages, so the attributed pattern cannot be verified from this source. (LLM, conf=0.70)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Importantly, it has also been demonstrated that patients exposed to certain agents (e.g. Agent Orange in Vietnam veterans, pesticides in agricultural worker, or 9/11 World Trade Center dust in first responders) or those suffering from specific conditions (such as HIV or Gaucher) have a higher prevalence of these clonal populations. 37-39 40,41 42”
§ Evolution of Multiple Myeloma from a Genomic Perspective > POSITIVE SELECTION IN HEALTHY INDIVIDUALS AND DURING MYELOMA PATHOGENESIS.
What the sources say
- Supportedcites [37] Landgren, 2018, Multiple myeloma and its precursor disease among firefighters exposed to the World Trade Center disaster, JAMA Oncol source
The Results section reports that WTC-exposed firefighters had a significantly higher age-standardized prevalence of overall MGUS than the comparison population (7.63 versus 4.34 per 100). This supports the WTC-exposure example attributed to this paper; the other exposures and conditions in the sentence have separate citations. (LLM, conf=0.92)
- Supportedcites [38] Landgren, 2015, Agent orange exposure and monoclonal gammopathy of undetermined significance: an operation Ranch Hand Veteran cohort study, JAMA Oncol source
The cited study supports the Agent Orange example in the multi-citation sentence. Its Discussion reports that MGUS prevalence was twofold higher among Ranch Hand veterans exposed to Agent Orange than among matched comparison veterans. The other exposures and conditions are not attributed specifically to this source. (LLM, conf=0.93)
- Supportedcites [39] Bibas, 2021, Prevalence of monoclonal gammopathy of undetermined significance (MGUS) at HIV diagnosis in individuals 18-40 years old: a possible HIV indicator condition, Blood Cancer J source
This source supports the HIV portion of the multiply cited sentence. Its concluding paragraph reports that MGUS prevalence was markedly higher in newly diagnosed HIV patients younger than 40 than in the general population. The other exposures and Gaucher disease are not attributed to this source specifically. (LLM, conf=0.91)
- Supportedcites [40] Nair, 2016, Clonal immunoglobulin against lysolipids in the origin of myeloma, N Engl J Med source
The cited paper supports the Gaucher disease portion of the sentence: its Abstract states that patients with Gaucher’s disease have an increased risk of monoclonal gammopathies. The sentence groups several citations after separate examples; this paper need not support the Agent Orange, pesticide, World Trade Center dust, or HIV examples. (LLM, conf=0.91)
- Partly supportedcites [41] Nair, 2018, Antigen-mediated regulation in monoclonal gammopathies and myeloma, JCI Insight sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) states that myeloma risk is markedly increased in patients with Gaucher disease, supporting the Gaucher portion of the claim. Our copy does not report higher prevalence of clonal populations after Agent Orange, pesticide, or World Trade Center dust exposure, or in people with HIV; nor does it directly compare the prevalence of clonal populations in Gaucher disease. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [42] Landgren, 2009, Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the agricultural health study, Blood source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
94 more claims · 57 with their cited sources checked
Create a free account to see all 124 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 19
- Probably not a substantial claim. 6
Citations
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., Martincorena, I., Alexandrov, L. B., Martin, S., Wedge, D. C., et al. (2016) · Nature · doi:10.1038/nature17676 · Cited by 2,218
Prevalence of monoclonal gammopathy of undetermined significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., Offord, J. R., Dispenzieri, A., Katzmann, J. A., & Melton, L. J. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054494 · Cited by 1,423
Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Mateos, M.-V., Hernández, M.-T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L. L., Rosiñol, L., Paiva, B., Palomera, L., Bargay, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300439 · Cited by 1,171
Landgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194241 · Cited by 1,127
Somatic mutant clones colonize the human esophagus with age
Martincorena, I., Fowler, J. C., Wabik, A., Lawson, A. R. J., Abascal, F., Hall, M. W. J., Cagan, A., Murai, K., Mahbubani, K., Stratton, M. R., et al. (2018) · Science · doi:10.1126/science.aau3879 · Cited by 1,113
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Davies, H., Glodzik, D., Morganella, S., Yates, L. R., Staaf, J., Zou, X., Ramakrishna, M., Martin, S., Boyault, S., Sieuwerts, A. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4292 · Cited by 1,086
The genetic architecture of multiple myeloma
Morgan, G. J., Walker, B. A., & Davies, F. E. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3257 · Cited by 913
Cited by
Carretero-Fernández, M., Cabrera-Serrano, A. J., Ruiz-Durán, L., Ibáñez, M., Bonilla, M., Mesa, F., Gutiérrez‐Bautista, J. F., Chahboun, R., Reyes‐Zurita, F. J., Martínez‐López, J., et al. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102796 · Cited by 1
“Collectively, these findings support a model in which germline susceptibility not only influences overall disease risk but may also shape the evolutionary trajectories of plasma cell neoplasia [64,91].”
One Grammar, Many Labels: Revisiting the Continuum of Myeloid Neoplasms
Tarantini, F., Cumbo, C., Anelli, L., et al. (2026) · Hematological Oncology · doi:10.1002/hon.70203
“…of undetermined significance as a temporal sequence of accelerating clonal evolution, this paradigm acknowledges that tumor progression is typically a gradual, multistep process driven by the sequential acquisition of genetic and epigenetic alterations rather than abrupt phenotypic switches [1–3].”
Sgherza, N., Resta, E., Curci, P., Battisti, O., Magazzino, O., Iannone, F., Albano, F., & Musto, P. (2026) · British Journal of Haematology · doi:10.1111/bjh.70687
“10 Regarding immunological alterations, both innate and adaptive immunity have been reported to be possibly involved in malignant transformation.”
Beyond exhaustion: T cell fitness for next generation of immunotherapy for hematological cancer
Kong, X., Su, Y., Zheng, H., Feng, Z., Huang, J., Zhang, L., & Li, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1895434 · Cited by 1
“MM is an instructive, but not universal, model (29, 30).”
Mateos, M., Gustine, J. N., Puertas, B., & Raje, N. S. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-00236 · Cited by 1
Metadata
- Authors
- Maura, F., Samur, M., & Munshi, N.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Harvard University (US)
- Corresponding author
- Maura, Francesco
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2026-03-26
- Volume
- 147
- Issue
- 13
- Pages
- 1423-1432
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC13077438
- OpenAlex
- W4417129847
- Cited by
- 8
- References
- 113
- Citations by year
- 2026: 8
- FWCI
- 1.35
- Type
- journal article
- Language
- en
- Open access
- green
- pmc.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Funders
- National Cancer Institute (P30CA008748, P01CA155258, R37CA289752)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- multiple myeloma, myelomagenesis, smoldering multiple myeloma, monoclonal gammopathy of undetermined significance, genetic susceptibility, germline mutations, hyperdiploidy, translocation, subclonal selection, immune surveillance, racial disparities, Agent Orange, agrochemical exposure, aging, disease progression, risk prediction
- MeSH terms
- Humans, Multiple Myeloma, Disease Progression, Evolution, Molecular, Genetic Predisposition to Disease, Genomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evolution of multiple myeloma from a genomic perspective. https://app.cochat.ai/papers/10.1182/blood.2024026313
- The paper
- Maura, F., Samur, M., & Munshi, N. (2026). Evolution of multiple myeloma from a genomic perspective. Blood. https://doi.org/10.1182/blood.2024026313
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.